Background: Globally, the use of community pharmacies and pharmacists in the delivery of vaccination services has been hampered by several factors, laws, and regulations that do not support pharmacists to participate in the delivery of vaccination services. With the advent of COVID-19 pandemic, many countries have included community pharmacists and pharmacies in vaccination services to improve coverage. This study described the delivery of vaccination services in community pharmacies using the COVID-19 experience and how their involvement impacted vaccination coverage in Nigeria. It also exposed how this experience can be used to support policy revisions to formally recognize pharmacists in immunization delivery.
Methods: A descriptive cross-sectional study was conducted among 474 community pharmacists in two southwestern States in Nigeria, using a semi-structured questionnaire. It determines the number of community pharmacists who have been trained in the delivery of vaccination services, the types of vaccination services provided, and vaccines administered in their pharmacies. Data were analyzed with descriptive and inferential statistics and -value at ≤ 0.05.
Results: Response rate was 86.7%. Less than half of the respondents (40.1%) had undergone vaccination training. Of the 129 (31.4%) respondents that provide vaccination services, 72 (55.8%) administer vaccines in their pharmacies. Out of these 72 respondents; 45 (62.5%) were administering vaccines before their involvement in COVID-19 vaccine administration; 57 (79.2%) of the health personnel who administer vaccines were pharmacists; 60 (83.3%) of them administer vaccines on request; 22 (30.6%) administered COVID-19 vaccines only; and only 7 (9.7%) of the respondents had administered over 500 doses of COVID-19 vaccines. Training in vaccination was associated with the vaccination services provided ( < 0.05). Respondents suggested government support through legal framework and policy review, training and empowering pharmacists in vaccine administration, and recognition of community pharmacists as PHC providers.
Conclusion: Training of community pharmacists in vaccination services had increased the number of respondents' involvement in the delivery of the services while the delivery of COVID-19 vaccination by community pharmacists had increased the number of clients vaccinated, hence improved coverage in Nigeria. Also, policy review and inclusion of community pharmacists and pharmacies in the national database will improve vaccination coverage and immunization service delivery in Nigeria.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11869367 | PMC |
http://dx.doi.org/10.1002/hcs2.130 | DOI Listing |
PLoS One
March 2025
Department of Pharmacology and Therapeutics, Usmanu Danfodiyo University, Sokoto, Nigeria.
Background: COVID-19 still poses a major public health challenge worldwide and vaccination remains one of the major interventions to control the disease. Different types of vaccines approved by the World Health Organization (WHO) are currently in use across the world to protect against the disease. This study assessed the prevalence and pattern of adverse events following immunization (AEFI) after receiving COVID-19 vaccine (the Oxford-AstraZeneca vaccine) among the adult population in Sokoto metropolis, North-west, Nigeria.
View Article and Find Full Text PDFJ Immunol
February 2025
Vaccine Research Institute, Université Paris-Est Créteil, Créteil, France.
The 2022 Mpox virus (MPXV) outbreak revitalized questions about immunity against MPXV and vaccinia-based vaccines (VAC-V), but studies are limited. We analyzed immunity against MPXV in individuals infected with MPXV or vaccinated with the licensed modified vaccinia Ankara (MVA) Bavarian Nordic or an experimental MVA-HIVB vaccine. The frequency of neutralizing antibody responders was higher among MPXV-infected individuals than MVA vaccinees.
View Article and Find Full Text PDFHealth Promot Chronic Dis Prev Can
March 2025
Evidence Synthesis and Knowledge Translation Unit, Centre for Surveillance and Applied Research, Health Promotion and Chronic Disease Prevention Branch, Public Health Agency of Canada, Ottawa, Ontario, Canada.
Introduction: We investigated the prevalence of new or persistent manifestations experienced by COVID-19 survivors at 3 or more months after their initial infection, collectively known as post-COVID-19 condition (PCC).
Methods: We searched four electronic databases and major grey literature resources for prospective studies, systematic reviews, authoritative reports and population surveys. A random-effects meta-analysis pooled the prevalence data of 22 symptoms and outcomes.
Mult Scler
March 2025
Department of Preventive Medicine and Epidemiology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona, Barcelona, Spain.
Background: Vaccination in patients with multiple sclerosis (PwMS) presents unique challenges. Disease-modifying therapies (DMTs) can increase infectious risks, though these are largely preventable through immunizations. However, DMTs can also reduce vaccine efficacy.
View Article and Find Full Text PDFEur J Immunol
March 2025
Sanquin Research and Landsteiner Laboratory, Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands.
Immunosenescence, age-related immune dysregulation, reduces immunity upon vaccinations and infections. Cytomegalovirus (CMV) infection results in declining naïve (T) and increasing terminally differentiated (T) T cell populations, further aggravating immune aging. Both immunosenescence and CMV have been speculated to hamper the formation of protective T-cell immunity against novel or emerging pathogens.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!